If the Trump administration wants to move forward with the Safe Importation Action Plan it announced last week, the FDA needs to reinstate unannounced inspections of drug manufacturing facilities in other countries, Sen. Chuck Grassley (R-Iowa) said Tuesday in a letter to Acting FDA Commissioner Ned Sharpless and Health and Human Services (HHS) Secretary Alex Azar.